NCT02724319View on ClinicalTrials.gov

Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy

CompletedOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

November 20, 2020

Study Completion Date

December 31, 2021

Conditions
Coronary Artery Disease
Interventions
DEVICE

SpartanRX

A buccal swap genetic sample will be collected from eligible patients who provide written informed consent for CYP2C19 testing. Genotyping will be performed by the SpartanRX system as a clinical test at the UF Health Pathology Laboratory in Jacksonville.

Trial Locations (1)

32209

University of Florida, Jacksonville

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Human Genome Research Institute (NHGRI)

NIH

lead

University of Florida

OTHER

NCT02724319 - Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy | Biotech Hunter | Biotech Hunter